1. Home
  2. VTS vs ANNX Comparison

VTS vs ANNX Comparison

Compare VTS & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vitesse Energy Inc.

VTS

Vitesse Energy Inc.

N/A

Current Price

$19.95

Market Cap

756.5M

Sector

Energy

ML Signal

N/A

Logo Annexon Inc.

ANNX

Annexon Inc.

N/A

Current Price

$5.51

Market Cap

730.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VTS
ANNX
Founded
2014
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
756.5M
730.4M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
VTS
ANNX
Price
$19.95
$5.51
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$26.50
$16.50
AVG Volume (30 Days)
441.7K
2.3M
Earning Date
06-04-2026
01-01-0001
Dividend Yield
11.52%
N/A
EPS Growth
N/A
42.94
EPS
0.64
N/A
Revenue
$273,989,000.00
N/A
Revenue This Year
$29.38
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$30.41
N/A
Revenue Growth
13.22
N/A
52 Week Low
$17.44
$1.29
52 Week High
$27.15
$7.18

Technical Indicators

Market Signals
Indicator
VTS
ANNX
Relative Strength Index (RSI) 44.96 52.37
Support Level $19.21 $4.69
Resistance Level $20.24 $5.61
Average True Range (ATR) 0.80 0.29
MACD -0.28 0.04
Stochastic Oscillator 44.42 81.58

Price Performance

Historical Comparison
VTS
ANNX

About VTS Vitesse Energy Inc.

Vitesse Energy Inc is an independent energy company focused on returning capital to stockholders through owning interests as a non-operator in oil and natural gas wells. It is engaged in the acquisition, development, and production of non-operated oil and natural gas properties in the United States that are generally operated by oil companies and are in the Williston Basin of North Dakota and Montana. The company also have properties in the Central Rockies, including the Denver-Julesburg Basin and the Powder River Basin.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: